Clinical trials: Epstein-Barr Virus Reactivation
Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation
A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
This is a single-center, prospective, randomized, open-label clinical trial with blinded endpoint assessment for patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation, Clinically Significant EBV DNAemia
- Trial name
- NCT07703657
- Testing
- Rituximab (Arm A), Standard Post-Transplant Supportive Care
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Yang Donglin
EBV Viremia, CMV Viremia
25BT056: Basket Study of Viral Cytotoxic T Lymphocytes
This study is evaluating the safety and effectiveness of virus-specific cytotoxic T lymphocytes (vCTLs) for treating difficult-to-control viral infections caused by cytomegalovirus (CMV), adenovirus (ADV), Epstein-Barr virus…
- Conditions
- EBV Viremia, CMV Viremia, BK Viremia, Adenovirus
- Trial name
- NCT07873970
- Testing
- Virus-Specific Cytotoxic T Lymphocytes (vCTLs)
- Volunteers
- 35 people
- Sponsor
- Children's Hospital of Philadelphia
Adenovirus Infection, EBV Infection
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)
This trial is designed to evaluate the feasibility, safety and efficacy of most closely HLA-matched multivirus specific CTL lines (CHM-CTLs) in HSCT patients with EBV, CMV or adenovirus infections that are persistent despite…
- Trial name
- CHALLAH (NCT00711035)
- Testing
- Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Baylor College of Medicine
Epstein-Barr Virus Infections, Cytomegalovirus Infections
R-MVST Cells for Treatment of Viral Infections
The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV)…
- Conditions
- Epstein-Barr Virus Infections, Cytomegalovirus Infections, Adenovirus, BK Virus Infection
- Trial name
- NCT05183490
- Testing
- Rapidly generated virus specific T (R-MVST) cells
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Columbia University
EBV Infection, CMV Infection
Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Subjects have a type of blood cell cancer, other blood disease or a genetic disease for which they received a stem cell transplant.
- Conditions
- EBV Infection, CMV Infection, Adenoviral Infection
- Trial name
- EAP CHALLAH (NCT01945619)
- Testing
- Trivirus-Specific CTLs
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine
Nasopharyngeal Cancinoma (NPC)
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Nearly all undifferentiated nasopharyngeal carcinoma (NPC) are associated with the Epstein-Barr Virus (EBV), which typically remains in a latent, non-immunogenic state within tumor cells.
- Trial name
- NCT07138989
- Testing
- Valganciclovir Hydrochloride Tablets, gemcitabine, cisplatin, and PD-1 antibody
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Epstein-Barr Virus (EBV), Healthy Volunteers
A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years
This multi-center, prospective, longitudinal cohort study is designed to gather immunological and clinical data on EBV reactivation in EBV seropositive adults aged 18 to 29 years.
- Trial name
- NCT07536048
- Testing
- Investigational Procedure
- Where
- 2 sites in Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
PD-1, EBV Infection
PD-1 Antibody for Reactive EBV After BMT
PD-1 antibody for reactivation of EBV after transplantation in patients with CAEBV/EBV-HLH
- Conditions
- PD-1, EBV Infection, Transplant
- Trial name
- NCT04690036
- Testing
- toripalimab injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
NPC
Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients
The purpose of this study is to investigate the EBV reactivation rate in post-radiation and remission NPC patients, evaluate the safety and tolerance of EGCG and analyze the observational correlation between EBV reactivation and…
- Trial name
- NPC (NCT01744587)
- Testing
- Epigallocatechin Gallate (EGCG)
- Where
- Taiwan
- Volunteers
- 353 people
- Sponsor
- National Health Research Institutes, Taiwan
Viral Infection, Viral Reactivation
Third Party Viral Specific T-cells (VSTs)
The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.
- Conditions
- Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
- Trial name
- NCT02532452
- Testing
- Viral Specific VST Infusion
- Where
- 4 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
EBV Infection After Allogenic HSCT
Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
The goal of this clinical trial is to learn if adding rituximab to the ATG-based Protocol can prevent Epstein-Barr virus (EBV) from reactivating in children who have received an allogeneic haploidentical hematopoietic stem cell…
- Trial name
- NCT07693881
- Testing
- Rituximab (R)
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Patients Undergoing Allogeneic Stem Cell Transplantation
Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
In patients after allogeneic stem cell transplantation reactivation of latent herpesviruses such as Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) is a frequent and life threatening complication requiring antiviral treatment.
- Trial name
- NCT02227641
- Testing
- CMV/EBV specific T-cell
- Where
- 6 sites in Germany
- Volunteers
- 50 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Allogeneic Stem Cell Transplant, Viral Infection
Donor-Derived Viral Specific T-cells (VSTs)
In this research study, the investigators want to learn more about the use of donor-derived viral specific T-cells (VSTs) to treat viral infections that occur after allogeneic stem cell transplant.
- Conditions
- Allogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation
- Trial name
- VSTs (NCT02048332)
- Testing
- Viral specific VST Infusion
- Where
- 3 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Graves Disease, Graves' Disease in Remission
Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation
Previous studies have proved that the lytic reactivation of latent Epstein-Barr virus (EBV) was significantly associated with the onset of Graves'disease (GD), however, the morbidity of GD and recurrence rate of hyperthyroidism…
- Conditions
- Graves Disease, Graves' Disease in Remission, Epstein-Barr Virus
- Trial name
- NCT06426758
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xiao-Ming Mao